Revance Therapeutics’ (RVNC) “Neutral” Rating Reiterated at Guggenheim

Guggenheim reiterated their neutral rating on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Monday, Marketbeat.com reports.

Other research analysts have also issued research reports about the stock. The Goldman Sachs Group dropped their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a neutral rating on the stock in a research note on Monday, May 13th. Stifel Nicolaus dropped their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a buy rating on the stock in a research note on Friday, August 9th. Needham & Company LLC reiterated a buy rating and issued a $12.00 price objective on shares of Revance Therapeutics in a research note on Friday, August 9th. Mizuho dropped their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a neutral rating on the stock in a research note on Friday, May 10th. Finally, William Blair reiterated a market perform rating on shares of Revance Therapeutics in a research note on Monday. Nine analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $11.89.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $6.58 on Monday. The company has a market cap of $689.72 million, a PE ratio of -1.81 and a beta of 0.98. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $19.88. The firm has a 50 day simple moving average of $3.34 and a 200 day simple moving average of $4.14.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to analysts’ expectations of $66.30 million. The firm’s revenue was up 20.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.80) EPS. On average, equities analysts predict that Revance Therapeutics will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Capital World Investors raised its holdings in Revance Therapeutics by 16.8% in the 1st quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock worth $68,612,000 after acquiring an additional 2,006,459 shares during the period. BNP Paribas Financial Markets raised its holdings in Revance Therapeutics by 342.1% in the 1st quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company’s stock worth $1,042,000 after acquiring an additional 163,809 shares during the period. Victory Capital Management Inc. bought a new position in Revance Therapeutics in the 4th quarter worth $93,000. Vanguard Group Inc. raised its holdings in Revance Therapeutics by 6.5% in the 1st quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock worth $26,560,000 after acquiring an additional 328,781 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Revance Therapeutics by 2.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,364 shares of the biopharmaceutical company’s stock worth $5,954,000 after acquiring an additional 13,826 shares during the period. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.